LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

31.28 0.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

31.22

Máximo

31.35

Métricas clave
By Trading Economics
Ingresos	11M 64M
Ventas	-3.2M 149M
P/B Media del Sector	18.052 49.701
BPA	0.79
Margen de beneficios	42.663
Empleados	182
EBITDA	2M 83M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+5.92% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	281M 3.8B
Apertura anterior	31.15
Cierre anterior	31.28

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 may 2026, 16:49 UTC

Ganancias

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 may 2026, 16:26 UTC

Principales Movimientos del Mercado

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 may 2026, 23:51 UTC

Charlas de Mercado

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 may 2026, 23:37 UTC

Ganancias

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 may 2026, 23:34 UTC

Charlas de Mercado

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 may 2026, 23:30 UTC

Charlas de Mercado

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 may 2026, 22:33 UTC

Adquisiciones, fusiones, absorciones

Conduent to Sell Public Transit Business to Modaxo for $164M

21 may 2026, 21:53 UTC

Ganancias

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 may 2026, 21:02 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 may 2026, 20:55 UTC

Ganancias

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 may 2026, 20:30 UTC

Acciones populares

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 may 2026, 20:20 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 may 2026, 20:20 UTC

Charlas de Mercado

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Adj EPS 3c >BULL

21 may 2026, 20:20 UTC

Ganancias

Webull 1Q Rev $159.9M >BULL

21 may 2026, 20:18 UTC

Charlas de Mercado

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 may 2026, 20:18 UTC

Ganancias

Webull 1Q Loss/Shr 4c

21 may 2026, 19:43 UTC

Charlas de Mercado

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 may 2026, 18:58 UTC

Ganancias

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 may 2026, 18:15 UTC

Charlas de Mercado

Gold Higher For Second Consecutive Day -- Market Talk

21 may 2026, 17:40 UTC

Charlas de Mercado

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 may 2026, 17:04 UTC

Charlas de Mercado

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 may 2026, 17:01 UTC

Ganancias

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Stellantis Targets Distant but Constructive -- Market Talk

21 may 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

5.92% repunte

Estimación a 12 Meses

Media 33.1 USD 5.92%

Máximo 35 USD

Mínimo 31.5 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.